# CCDC6

Source: https://onco.cc/targets/ccdc6/  
OnCo record `ccdc6` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.

## Summary

Acts as a structural scaffold that organises free PP2Ac into a configuration that FBXO42 can recognise and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination.

Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes clinical 0.97, literature 0.94, genetic association 0.00, somatic mutation 0.82, animal model 0.38). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Basal Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: coiled-coil domain containing 6; Coiled-coil domain-containing protein 6; H4; PTC1; TST1; D10S170
- Tags: cancer-genes-wave
- Symbol: CCDC6
- Class: tumor-suppressor
- Biology: Acts as a structural scaffold that organises free PP2Ac into a configuration that FBXO42 can recognise and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination. Location: Cytoplasm; Cytoplasm, cytoskeleton (UniProt). Locus 10q21.2 (HGNC).
- Where found: Lung cancer: Open Targets association 0.72 with lung cancer (MONDO_0008903); Thyroid cancer: Open Targets association 0.70 with thyroid cancer (MONDO_0002108); Neuroendocrine tumours: Open Targets association 0.63 with neuroendocrine neoplasm (MONDO_0019496); Non-small-cell lung cancer: Open Targets association 0.72 with non-small cell lung carcinoma (MONDO_0005233); Basal cell carcinoma: IntOGen driver in 1 cohort (BCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:18782: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18782
- UniProt Q16204: https://www.uniprot.org/uniprotkb/Q16204/entry
- NCBI Gene 8030: https://www.ncbi.nlm.nih.gov/gene/8030
- Ensembl ENSG00000108091: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108091

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)

---
JSON: https://onco.cc/api/v1/entities/ccdc6.json